Multimodal Molecular Imaging and Therapy Platform

A next-generation platform for personalized medicine, integrating targeted molecular imaging and therapy compounds, real-time monitoring, and adaptive treatment optimization, enabling precise and effective disease diagnosis and treatment.

The original patent disclosed a multivalent molecular imaging and/or targeted drug delivery method, but it had limitations in terms of real-time monitoring and adaptive treatment optimization. The new inventive concept addresses these limitations by introducing a multimodal platform that co-administers targeted molecular imaging and therapy compounds, enabling real-time monitoring and adaptive treatment optimization.

The multimodal platform consists of a targeted molecular imaging compound and a targeted therapeutic compound, designed to target the same biomarker on a biological subject. The platform enables real-time monitoring of the biological subject using a detection device, and the detection data is used to optimize the administration of the targeted therapeutic compound. The platform can be used for personalized medicine, where the targeted molecular imaging compound is administered to a biological subject, detected using a detection device, and the detection data is used to select a targeted therapeutic compound for treating the biological subject.

The new inventive concept introduces the concept of real-time monitoring and adaptive treatment optimization, which is not present in the original patent. The co-administration of targeted molecular imaging and therapy compounds, and the use of detection data to optimize treatment, are novel and non-obvious features that provide a significant improvement over the original patent.

Alternative embodiments of the multimodal platform could include the use of different types of detection devices, such as MRI or PET scanners, or the use of different types of targeted molecular imaging and therapy compounds. Variations of the platform could also include the integration of artificial intelligence or machine learning algorithms to optimize treatment based on detection data.

The multimodal platform has significant commercial potential in the fields of personalized medicine, cancer treatment, and molecular imaging. The platform could be used in hospitals and research institutions, and could be marketed to pharmaceutical companies and biotechnology companies developing targeted therapies.